Oak Ridge Investments LLC Cuts Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Oak Ridge Investments LLC trimmed its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 10.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,831 shares of the company’s stock after selling 211 shares during the period. Oak Ridge Investments LLC’s holdings in IDEXX Laboratories were worth $989,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Patron Partners LLC boosted its stake in shares of IDEXX Laboratories by 2.7% during the fourth quarter. Patron Partners LLC now owns 765 shares of the company’s stock worth $425,000 after buying an additional 20 shares during the period. NewEdge Wealth LLC boosted its stake in shares of IDEXX Laboratories by 3.1% during the fourth quarter. NewEdge Wealth LLC now owns 659 shares of the company’s stock worth $366,000 after buying an additional 20 shares during the period. Manchester Capital Management LLC boosted its stake in shares of IDEXX Laboratories by 11.9% during the fourth quarter. Manchester Capital Management LLC now owns 188 shares of the company’s stock worth $104,000 after buying an additional 20 shares during the period. Phoenix Holdings Ltd. raised its holdings in IDEXX Laboratories by 2.8% during the third quarter. Phoenix Holdings Ltd. now owns 769 shares of the company’s stock worth $338,000 after purchasing an additional 21 shares in the last quarter. Finally, BluePath Capital Management LLC raised its holdings in IDEXX Laboratories by 1.8% during the fourth quarter. BluePath Capital Management LLC now owns 1,197 shares of the company’s stock worth $663,000 after purchasing an additional 21 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock traded up $8.51 during mid-day trading on Friday, reaching $486.00. The company had a trading volume of 381,823 shares, compared to its average volume of 492,080. IDEXX Laboratories, Inc. has a 1 year low of $372.50 and a 1 year high of $583.39. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.57 and a quick ratio of 1.16. The company has a market capitalization of $40.14 billion, a P/E ratio of 47.05, a P/E/G ratio of 3.90 and a beta of 1.32. The stock’s 50-day simple moving average is $500.35 and its 200-day simple moving average is $524.55.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Wednesday, May 1st. The company reported $2.81 earnings per share for the quarter, topping analysts’ consensus estimates of $2.68 by $0.13. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. The business had revenue of $964.10 million during the quarter, compared to analysts’ expectations of $965.43 million. On average, equities analysts predict that IDEXX Laboratories, Inc. will post 11.03 EPS for the current year.

Insider Transactions at IDEXX Laboratories

In other news, Director Bruce L. Claflin sold 200 shares of the firm’s stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $540.80, for a total transaction of $108,160.00. Following the completion of the transaction, the director now directly owns 161 shares of the company’s stock, valued at approximately $87,068.80. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 2.18% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Barclays cut their price target on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a report on Thursday, May 2nd. Stifel Nicolaus cut their price target on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a report on Monday, June 24th. William Blair reissued an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. StockNews.com raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Friday, June 14th. Finally, Morgan Stanley cut their price target on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating for the company in a report on Tuesday, May 14th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $586.63.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.